Safety and efficacy of azacitidine in myelodysplastic syndromes

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 221-229

  Vigil, Carlos E ^a   Martin Santos, Taida ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Azacitidine; Hypomethylating agents; MDS

Indexed keywords

AZACITIDINE; CYTARABINE; ENTINOSTAT; ETANERCEPT; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MOCETINOSTAT; RETINOIC ACID; VALPROIC ACID; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW SUPPRESSION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CREATININE BLOOD LEVEL; CYTOPENIA; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; GERIATRIC PATIENT; HUMAN; INFECTION; INJECTION SITE ERYTHEMA; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; OFF LABEL DRUG USE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT FAILURE; VOMITING; DISEASE COURSE; DRUG ADMINISTRATION; SURVIVAL;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; SURVIVAL;

EID: 79952050717     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S3143     Document Type: Review

References (54)

1. Issa JP, Kantarjian HM, Kirkpatrick P. Azacitidine. Nat Rev Drug Discov. 2005;4(4):275-276.
2. Gobler AB, Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep. 1987;71(10):959-964.
3. Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324-1341.
4. Cataldo V, Cortes J, Quintas-Cardama A. Azacitidine for the treatment of Myelodysplastic syndrome. Expert Rev Anticancer Ther. 2009;9(7): 875-884.
5. Saiki JH, Bodey GP, Hewlett JS, et al. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study. Cancer. 1981;47(7):1739-1742.
6. Vogler WR, Miller DS, Keller JW. 5 Azacitidine (NSC102816): a new drug for the treatment of myeloblastic leukemia. Blood. 1976;48(3): 331-337.
7. Mc Credie KB, Bodey GP, Burgess MA, et al. Treatment of acute leukemia with 5-azacytidine (NSC 102816). Cancer Chemother Rep. 1973;57(3):319-323.
8. Goldberg J, Gryn J, Raza A, et al. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a Leukemia Intergroup Study. Am J Hematol. 1993;43(4):286-290.
9. Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol. 1994;68:A12.
10. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002; 20(10):2429-2440.
11. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-3903.
12. Fenaux P, Mufti G, Santini V, et al. Azacitidine treatments prolong overall survival in higher risk MDS patients compared with conventional care regimens: results of the AZA-001 phase III study. Blood (ASH Annual Meeting Abstracts). 2007;110:250.
13. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
14. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia. 2007;21:1937-1944.
15. Silverman LR, Fenaux P, Mufti GJ, et al. The effects of continued azacytidine (AZA) treatments cycles on response in higher-risk patients with myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts). 2008;112(11):227.
16. Lyons R, Cosgriff T, Modi S, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27(11):1850-1856.
17. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcomes. Blood. 2004;104:579-585.
18. Grovdal M, Khan R, Aggerholm A, et al. Maintenance treatment with 5-azacitidine for patients with high-risk MDS or acute myeloid leukemia following MDS in complete remission after induction chemotherapy. Blood (ASH Annual Meeting Abstracts). 2008;112:223.
19. Ravandi F, Jean-Pierre I, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009;115:5746-5751.
20. Field T, Perkins J, Alsina M, et al. Pre-transplant 5-azacitidine may improve outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts). 2006;108:3664.
21. Pinto A, Maio M, Attadia V, et al. Modulation of HLA-DR antigen expression in human myeloid leukemic cells by cytarabine and 5-aza-2'-deoxycytidine. Lancet. 1984;2:867-868.
22. Coral S, Sigalotti L, Gasparollo A, et al. Prolonged up regulation of the expression of HLA class I antigen and co stimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycitidine. J Immunother. 1999;22:16-24.
23. Jabbour E, Giralt S, Kantarjian H, et al. Low-dose azacitidine after allogenic stem cell transplantation for acute leukemia. Cancer. 2009; 115:1899-905.
24. Kim HP, Leonard WJ. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med. 2007;204:1543-1551.
25. Tang KF, He CX, Zeng GL, et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun. 2008;370:578-583.
26. Sanchez-Abarca L, Gutierrez-Cosio S, Santamaria C, et al. Immunomodulatory effect of 5-azacytidine: potential role in the transplant setting. Blood. 2010;115:107-121.
27. de Lima M, Padua L, Giralt S, et al. A dose schedule finding study of maintenance therapy with low-dose 5-azacitidine after allogenic hematopoietic stem cell transplantation for high risk AML or MDS. Blood (ASH Annual Meeting Abstracts). 2007;110:3012
28. de Lima, Padua L, Giralt S, et al. Maintenance therapy with low-dose Azacitidine after allogenic hematopoietic stem cell transplantation for relapsed or refractory AML or MDS: dose and schedule finding study. Blood (ASH Annual Meeting Abstracts). 2008;112:1134.
29. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
30. Rosetti J, Shadduck R, Thatikonda C, et al. Low-dose Azacitidine for relapse of MDS/AML after unrelated donor peripheral blood stem cell transplantation. Blood (ASH Annual Meeting Abstracts). 2007;110:5034.
31. Seymour J, Fenaux P, Silverman L, et al. Effects of azacitidine vs conventional care regimens in elderly (.75 years) patients with myelodysplastic syndromes from the AZA-001 survival trial. Blood (ASH Annual Meeting Abstracts). 2008;112:3629.
32. Itzykson R, Thepot S, Achour B, et al. Azacytidine in MDS in patients.80 years: results of the French ATU Program. Blood (ASH Annual Meeting Abstracts). 2009;114:1773.
33. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2008;22: 538-543.
34. Grinblatt D, Narang M, Malone J, et al. Treatment of patients with lowrisk myelodysplastic syndromes receiving azacitidine who are enrolled in AVIDA, a longitudinal patient registry. Blood (ASH Annual Meeting Abstracts). 2008;112:1646.
35. Musto P, Maurillo L, Spagnoli A, et al. Azacitidine for the treatment of lower-risk myelodysplastic syndrome. Cancer. 2010;116:1485-1494.
36. Garcia-Manero G, Stoltz ML, Ward MR, et al. A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008;22:1680-1684.
37. Garcia-Manero G, Gore S, Skikne B, et al. A phase I, open-label, dose escalation study to evaluate safety, pharmacokinetics, pharmacodynamics of oral azacitidine in patients with myelodysplastic syndrome or acute myelogenous leukemia. Blood (ASH Annual Meeting Abstracts). 2009;114:117.
38. MacBeth K, Laille E, Ning Y, et al. A comparative pharmacokinetic/ pharmacodynamic evaluation of azacitidine following subcutaneous and oral administration in subjects with Myelodysplastic syndrome or acute myelogenous leukemia, results from a phase I study. Blood (ASH Annual Meeting Abstracts). 2009;114:1772.
39. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase I/II study of the combination of 5-aza-2'deoxycitidine with valproic acid in patients with leukemia. Blood. 2006;108(10);3271-3279.
40. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279.
41. Voso MT, Santini V, Finelli C, et al. Valproic acid therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res. 2009;15(15):5002-5007.
42. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol. 2008;26:abstract 7000.
43. Soriano A, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2006;110(7):2302-2308.
44. Gore S, Jiemjit A, Silverman LR, et al. Combined methyltransferase/histone deacetylase inhibition with 5-azacitidine and MS-275 in patients with MDS, CMMoL and AML: clinical response, histone acetylation and DNA damage. Blood (ASH Annual Meeting Abstracts). 2006;108(11):517.
45. Garcia-Manero G, Assouline S, Cortes J, et al. Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112(4):981-989.
46. Raza A, Mehdi M, Mumtaz M, et al. Combination of 5-Azacitidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113:1596-1604.
47. Sekeres M, List F, Cuthbertson D, et al. Final results from a phase I combination study of lenalidomide and azacitidine in patients with higherrisk MDS. Blood (ASH Annual Meeting Abstracts) 2008;112:221.
48. Holsinger AL, Ramakishnan A, Storer B, et al. Therapy of Myelodysplastic Syndrome with azacitidine given in combination with etanercept: a phase II study. Blood (ASH Annual Meeting Abstracts). 2007;110:1452.
49. Michaelis L, Shafer D, Barton K, et al. Azacitidine and low-dose gemtuzumab ozogamicin for the treatment of poor-risk AML and MDS including relapsed refractory disease. Blood (ASH Annual Meeting Abstracts). 2009;114:1034.
50. Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. In press. DOI: 10.1002/cncr.25247
51. Santini V, Fenaux P, Mufti G, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. In press. DOI: 10.1111/j.1600-0609.2010.01456.x
52. Peterson BA, Collins AJ, Vogelzang NJ, et al. 5-Azacytidine and renal tubular acidosis. Blood. 1981;57(1):182-185.
53. Bellet RD, Mastrangelo MJ, Engstrom PF, et al. Clinical Trial with subcutaneously administered 5-azacytidine (NSC-102816). Cancer Chemother Rep. 1974;58:217-228.
54. Vidaza (azacitidine) package insert. Boulder, CO: Celgene Corporation; 2009.